Orgenesis Inc (NASDAQ:ORGS), a developer of advanced cell therapies, has struck a deal with Columbia University under which it will fund research to develop a cellular vaccination product platform.
Columbia University has created a patented dual-vaccine – focusing on pancreatic, liver and bile duct cancers – that uses whole cancer cells as a source of antigens and the patient’s own immune cells.
Under the terms of the research pact, Orgenesis will receive an exclusive license on the technology developed at Columbia.
For article click here: https://bit.ly/2IAUdja
Mark Cohen, Senior Partner and Chair of the Life Science Practice Group of Pearl Cohen represents Orgenesis in intellectual property and commercial matters.
